A Randomized, Double-blind, Single Ascending Dose Study to Determine the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3772847 Administered Subcutaneously in Healthy Participants

GSK3772847, an anti-interleukin (IL) 33-receptor monoclonal antibody, is a novel treatment
for asthma. The purpose of this study to evaluate the safety and tolerability, PK and PD of
single ascending doses of GSK3772847 administered subcutaneously (SC) to healthy
participants. This study will also establish the bioavailability of SC formulation and
evaluate the safety in particular injection site tolerability of route. Participants will
either receive a single dose of 70 milligram (mg) GSK3772847 or placebo in (Cohort 1) and 140
mg GSK3772847 or placebo in Cohorts 2, 3 (Japanese participants) and 4 (Chinese
participants). The site of injection will be upper arm; abdomen or thigh for cohorts 1 and 2
with cohorts 3 and 4 will receive injections in the upper arm only. Approximately, the total
duration of study will be up to 89 days.